Gupta GP, Massagué J (2006) Cancer metastasis: building a framework. Cell 127:679–695. https://doi.org/10.1016/j.cell.2006.11.001

Article  CAS  PubMed  Google Scholar 

Gundem G, Van Loo P, Kremeyer B et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520:353–357. https://doi.org/10.1038/nature14347 (Erratum in: Nature. 2020 Aug;584(7820):E18)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meta-analysis of Randomized trials in Cancer of the Prostate MARCAP Consortium investigators, Ma TM, Chu FI, Sandler H et al (2022) Local failure events in prostate cancer treated with radiotherapy: a pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in cancer of the prostate consortium (LEVIATHAN). Eur Urol. https://doi.org/10.1016/j.eururo.2022.07.011

Article  Google Scholar 

Niibe Y, Kazumoto T, Toita T et al (2006) Frequency and characteristics of isolated para-aortic lymph node recurrence in pts. with uterine cervical carcinoma in Japan: a multi-institutional study. Gynecol Oncol 103:435–438. https://doi.org/10.1016/j.ygyno.2006.03.034

Article  PubMed  Google Scholar 

Niibe Y, Kenjo M, Kazumoto T et al (2006) Multi-institutional study of radiation therapy for isolated para-aortic lymph node recurrence in uterine cervical carcinoma: 84 subjects of a population of more than 5,000. Int J Radiat Oncol Biol Phys 66:1366–1369. https://doi.org/10.1016/j.ijrobp.2006.07.1384

Article  PubMed  Google Scholar 

Niibe Y, Kuranami M, Matsunaga K et al (2008) Value of high-dose radiation therapy for isolated osseous metastasis in breast cancer in terms of oligo-recurrence. Anticancer Res 28:3929–3931

PubMed  Google Scholar 

Liu W, Laitinen S, Khan S et al (2009) Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 15:559–565. https://doi.org/10.1038/nm.1944 (Erratum in: Nat Med. 2009 Jul;15(7):819)

Article  CAS  PubMed  PubMed Central  Google Scholar 

James ND, de Bono JS, Spears MR et al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377:338–351. https://doi.org/10.1056/NEJMoa1702900

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352–360. https://doi.org/10.1056/NEJMoa1704174

Article  CAS  PubMed  Google Scholar 

CONDOR Study Group, Morris MJ, Rowe SP, Gorin MA et al (2021) Diagnostic performance of 18F‑DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res 27:3674–3682. https://doi.org/10.1158/1078-0432.CCR-20-4573

Article  PubMed Central  Google Scholar 

Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36:446–453. https://doi.org/10.1200/JCO.2017.75.4853

Article  CAS  PubMed  Google Scholar 

Siva S, Bressel M, Murphy DG et al (2018) Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol 74:455–462. https://doi.org/10.1016/j.eururo.2018.06.004

Article  PubMed  Google Scholar 

Kneebone A, Hruby G, Ainsworth H et al (2018) Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission Tomography. Eur Urol 1:531–537. https://doi.org/10.1016/j.euo.2018.04.017

Article  Google Scholar 

Phillips R, Shi WY, Deek M et al (2020) Outcomes of observation vs Stereotactic ablative radiation for Oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6:650–659. https://doi.org/10.1001/jamaoncol.2020.0147

Article  PubMed  PubMed Central  Google Scholar 

Supiot S, Vaugier L, Pasquier D et al (2021) OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer. Eur Urol 80:405–414. https://doi.org/10.1016/j.eururo.2021.06.010

Article  CAS  PubMed  Google Scholar 

Glicksman RM, Metser U, Vines D et al (2021) Curative-intent metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer: a prospective phase II trial testing the Oligometastasis hypothesis. Eur Urol 80:374–382. https://doi.org/10.1016/j.eururo.2021.02.031

Article  CAS  PubMed  Google Scholar 

Noda M, Taguchi S, Shiraishi K et al (2024) Six-year outcomes of robot-assisted radical prostatectomy versus volumetric modulated arc therapy for localized prostate cancer: A propensity score-matched analysis. Strahlenther Onkol. https://doi.org/10.1007/s00066-023-02192-5

Article  PubMed  PubMed Central  Google Scholar 

Rogasch JM, Cash H, Zschaeck S et al (2018) Ga-68-PSMA PET/CT in treatment-naïve pts. with prostate cancer: which clinical parameters and risk stratification systems best predict PSMA-positive metastases? Prostate. https://doi.org/10.1002/pros.23685

Article  PubMed  Google Scholar 

Hanna GG, Murray L, Patel R et al (2018) UK consensus on normal tissue dose constraints for stereotactic radiotherapy. Clin Oncol 30:5–14. https://doi.org/10.1016/j.clon.2017.09.007

Article  CAS  Google Scholar 

Schechter NR, Brown DW, Bovi JA et al (2020) ACR-ASTRO practice parameter for communication: radiation oncology. Am J Clin Oncol 43:553–558. https://doi.org/10.1097/COC.0000000000000707

Article  PubMed  Google Scholar 

Chao ST, Dad LK, Dawson LA et al (2020) ACR-ASTRO practice parameter for the performance of Stereotactic body radiation therapy. Am J Clin Oncol 43:545–552. https://doi.org/10.1097/COC.0000000000000706

Article  PubMed  Google Scholar 

Gerhard SG, Palma DA, Arifin AJ et al (2021) Organ at risk dose constraints in SABR: a systematic review of active clinical trials. Pract Radiat Oncol 11:e355–e365. https://doi.org/10.1016/j.prro.2021.03.005

Article  PubMed  Google Scholar 

King CR, Brooks JD, Gill H et al (2012) Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 82:877–882. https://doi.org/10.1016/j.ijrobp.2010.11.054

Article  PubMed  Google Scholar 

Hurmuz P, Onal C, Ozyigit G et al (2020) Treatment outcomes of metastasis-directed treatment using 68Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002). Strahlenther Onkol 196:1034–1043. https://doi.org/10.1007/s00066-020-01660-6

Article  PubMed  Google Scholar 

Afshar-Oromieh A, Avtzi E, Giesel FL et al (2015) The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42:197–209. https://doi.org/10.1007/s00259-014-2949-6

Article  CAS  PubMed  Google Scholar 

Wang R, Shen G, Huang M et al (2021) The diagnostic role of 18F‑choline, 18F‑Fluciclovine and 18F‑PSMA PET/CT in the detection of prostate cancer with biochemical recurrence: a meta-analysis. Front Oncol 11:684629. https://doi.org/10.3389/fonc.2021.684629

Article  CAS  PubMed  PubMed Central  Google Scholar 

von Eyben FE, Picchio M, von Eyben R et al (2018) 68ga-labeled prostate-specific membrane antigen Ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus 4:686–693. https://doi.org/10.1016/j.euf.2016.11.002

Article  Google Scholar 

Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR (2019) Metaanalysis of 68ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med 60:786–793. https://doi.org/10.2967/jnumed.118.219501

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perera M, Papa N, Roberts M et al (2020) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 77:403–417. https://doi.org/10.1016/j.eururo.2019.01.049

Article